Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403059 | 1.00 | SLC22A6 (0.36) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL1195035 | 0.82 | KDM4E (0.41) | SLC22A6GPR84MAPTKDM4EATM | |
| SCHEMBL16903725 | 0.76 | HDAC3 (0.34) | — | |
| SCHEMBL31197098 | 0.74 | FFAR4 (0.49) | GPR84 | |
| SCHEMBL31197079 | 0.74 | FFAR4 (0.49) | GPR84 | |
| SCHEMBL55046 | 0.74 | — | — | |
| SCHEMBL265475 | 0.74 | — | — | |
| SCHEMBL27643 | 0.74 | — | — | |
| SCHEMBL28972721 | 0.72 | — | — | |
| Propane SCHEMBL29018759 | 0.72 | SLC22A6 (0.63) | SLC22A6GPR84MAPTGABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274401-B2 | STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING 7-SUBSTITUTED-3,5-DIHYDROXYHEPTANOIC ACIDS OR 7-SUBSTITUTED-3,5-DIHYDROXYHEPTENOIC ACIDS | TEVA PHARMA (IL) | 2014-08-13 | — | — | EP | claimed |
| EP-2382970-B1 | Stable Pharmaceutical Compositions Containing 7-Substituted-3,5-Dihydroxyheptanoic Acids or 7-Substituted-3,5-Dihydroxyheptenoic Acids | TEVA PHARMA (IL) | 2013-01-09 | — | — | EP | claimed |
| EP-1274401-B1 | STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING 7-SUBSTITUTED-3,5-DIHYDROXYHEPTANOIC ACIDS OR 7-SUBSTITUTED-3,5-DIHYDROXYHEPTENOIC ACIDS | TEVA PHARMA (IL) | 2011-09-14 | — | — | EP | claimed |
| US-8227612-B2 | Quinoline compound and pharmaceutical composition, preparation method and uses thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2012-07-24 | — | — | US | disclosed |
| US-8193215-B2 | Thieno[2 3-b]pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| EP-2284158-A1 | QUINOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF | Shanghai Institute of Pharmaceutical Industry (CN) | 2011-02-16 | — | — | EP | disclosed |
| US-20110021561-A1 | QUINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USES THEREOF | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2011-01-27 | — | — | US | disclosed |
| WO-2010077062-A2 | PREPARATION METHOD OF STATIN COMPOUND AND BENZOTHIAZOLYL SULFONE COMPOUND USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2010-07-08 | — | — | WO | disclosed |
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | XENTION LIMITED (GB) | 2010-02-18 | — | — | US | disclosed |
| US-7576212-B2 | Thieno[2,3-B] pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| EP-1262476-B1 | PROCESSES FOR PREPARING QUINOLINE DERIVATIVES AND INTERMEDIATES THEREOF | NISSAN CHEMICAL IND LTD (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-20060183768-A1 | Compounds | XENTION DISCOVERY LTD. (GB) | 2006-08-17 | — | — | US | disclosed |
| US-5393780-A | Anticholesterol, antilipemic agents | FUJIREBIO INC. (JP) | 1995-02-28 | — | — | US | disclosed |
| EP-0616999-A2 | 4-Fluorobiphenyl derivatives | FUJIREBIO Inc. (JP) | 1994-09-28 | — | — | EP | disclosed |
| US-4970077-A | ENZYME INHIBITORS, ANTICHOLESTEROL AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021561-A1 | QUINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USES THEREOF | HMGCR, DHCR7, PCSK9 | SLC22A6 1082/4885GPR84 1882/4885MAPT 3057/4885 |
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | SCN8A, SCN1B, SCN2B | SLC22A6 1131/4885GPR84 784/4885MAPT 4755/4885 |
| US-20060183768-A1 | Compounds | SCN7A, CBR3, SCN8A | SLC22A6 923/4885GPR84 600/4885MAPT 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.